MX2023015070A - Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo. - Google Patents
Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo.Info
- Publication number
- MX2023015070A MX2023015070A MX2023015070A MX2023015070A MX2023015070A MX 2023015070 A MX2023015070 A MX 2023015070A MX 2023015070 A MX2023015070 A MX 2023015070A MX 2023015070 A MX2023015070 A MX 2023015070A MX 2023015070 A MX2023015070 A MX 2023015070A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen
- antibody
- binding fragment
- medical use
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110722124 | 2021-06-28 | ||
| PCT/CN2022/101780 WO2023274201A1 (zh) | 2021-06-28 | 2022-06-28 | 抗cd40抗体、其抗原结合片段及医药用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023015070A true MX2023015070A (es) | 2024-01-17 |
Family
ID=84690362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023015070A MX2023015070A (es) | 2021-06-28 | 2022-06-28 | Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250340661A1 (enExample) |
| EP (1) | EP4365200A4 (enExample) |
| JP (1) | JP2024523514A (enExample) |
| KR (1) | KR20240026185A (enExample) |
| CN (1) | CN117295764A (enExample) |
| AU (1) | AU2022301422A1 (enExample) |
| BR (1) | BR112023026111A2 (enExample) |
| CA (1) | CA3223842A1 (enExample) |
| MX (1) | MX2023015070A (enExample) |
| TW (1) | TW202309095A (enExample) |
| WO (1) | WO2023274201A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202430226A (zh) * | 2022-12-28 | 2024-08-01 | 大陸商上海盛迪醫藥有限公司 | 抗cd40抗體藥物偶聯物、其製備方法及其醫藥用途 |
| TW202432588A (zh) | 2022-12-28 | 2024-08-16 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 一種cd40結合分子的組成物及醫藥用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| EP1322383B9 (en) * | 2000-10-02 | 2006-09-06 | Chiron Corporation | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| ES2551439T5 (es) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fragmentos Fab de anticuerpos modificados |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
| CA2737241C (en) | 2008-09-26 | 2017-08-29 | Ucb Pharma S.A. | Multivalent antibody fusion proteins |
| HUE049849T2 (hu) * | 2010-03-31 | 2020-10-28 | Boehringer Ingelheim Int | Anti-CD40 antitestek |
| AR083847A1 (es) * | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| TR201909840T4 (tr) * | 2011-03-11 | 2019-07-22 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antikorları ve kullanımları. |
| GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| WO2016028810A1 (en) * | 2014-08-18 | 2016-02-25 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| BR112018004296B1 (pt) * | 2015-09-04 | 2020-05-05 | Primatope Therapeutics Inc | anticorpos anti-cd40 humanizados e usos dos mesmos |
| BR112018006251A2 (pt) * | 2015-09-30 | 2018-10-16 | Janssen Biotech Inc | anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso |
| CN110546164B (zh) * | 2016-11-11 | 2023-10-20 | 锦湖Ht株式会社 | 特异性结合cd40的抗体及其用途 |
| AU2018278051A1 (en) * | 2017-06-01 | 2020-01-30 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof |
| WO2020006347A1 (en) * | 2018-06-29 | 2020-01-02 | Boehringer Ingelheim International Gmbh | Anti-cd40 antibodies for use in treating autoimmune disease |
| CN111454364B (zh) * | 2019-03-04 | 2021-03-02 | 北京天广实生物技术股份有限公司 | 结合cd40的抗体及其用途 |
-
2022
- 2022-06-28 JP JP2023579198A patent/JP2024523514A/ja active Pending
- 2022-06-28 TW TW111124104A patent/TW202309095A/zh unknown
- 2022-06-28 US US18/573,381 patent/US20250340661A1/en active Pending
- 2022-06-28 CA CA3223842A patent/CA3223842A1/en active Pending
- 2022-06-28 BR BR112023026111A patent/BR112023026111A2/pt not_active Application Discontinuation
- 2022-06-28 KR KR1020247001972A patent/KR20240026185A/ko active Pending
- 2022-06-28 AU AU2022301422A patent/AU2022301422A1/en active Pending
- 2022-06-28 CN CN202280034096.6A patent/CN117295764A/zh active Pending
- 2022-06-28 EP EP22832015.6A patent/EP4365200A4/en active Pending
- 2022-06-28 MX MX2023015070A patent/MX2023015070A/es unknown
- 2022-06-28 WO PCT/CN2022/101780 patent/WO2023274201A1/zh not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240026185A (ko) | 2024-02-27 |
| EP4365200A1 (en) | 2024-05-08 |
| EP4365200A4 (en) | 2025-04-09 |
| JP2024523514A (ja) | 2024-06-28 |
| TW202309095A (zh) | 2023-03-01 |
| CA3223842A1 (en) | 2023-01-05 |
| WO2023274201A1 (zh) | 2023-01-05 |
| CN117295764A (zh) | 2023-12-26 |
| BR112023026111A2 (pt) | 2024-03-05 |
| US20250340661A1 (en) | 2025-11-06 |
| AU2022301422A1 (en) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000263A1 (es) | Conjugado de anticuerpo monoclonal contra bcma-fármaco. | |
| MX2020008977A (es) | Formulaciones de anticuerpos de her2 subcutaneas. | |
| MX2021013225A (es) | Composiciones y metodos para el tratamiento del cancer utilizando una terapia de celulas t modificadas de cd8. | |
| MX2024013963A (es) | Un antagonista de il-4r util para el tratamiento o la prevencion del asma | |
| ECSP23019525A (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos | |
| MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
| CO2020013252A2 (es) | Dosificación subcutánea de anticuerpos anti-cd38 | |
| MX2021009041A (es) | Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| ECSP18096095A (es) | Anticuerpos a la alfa-sinucleína y usos de los mismos | |
| CL2020002075A1 (es) | Métodos para tratar el cáncer con anticuerpos anti-pd1. | |
| CO2021008665A2 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
| CO2021015793A2 (es) | Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 | |
| CO2022004743A2 (es) | Anticuerpos dirigidos a flt3 y uso de los mismos | |
| ECSP20063690A (es) | Anticuerpos | |
| CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| MX2022001022A (es) | Anticuerpo biespecifico anti-her2/anti-4-1bb y uso del mismo. | |
| MX2019012865A (es) | Anticuerpos anti-interferon gamma y usos de los mismos. | |
| MX2022001027A (es) | Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo. | |
| CO2023002375A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| MX2023015070A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo. | |
| MX2022001065A (es) | Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo. | |
| CL2025000581A1 (es) | Estructuras derivadas de tn3 específicas de cd40l; tratamiento, prevención del síndrome de sjögren |